Spurs Sports and Entertainment and Canon Medical Partnership To Benefit High-Performance Athletes and Weekend Warriors

Spurs Sports and Entertainment: announced today a new partnership between Canon Medical Systems USA, Inc. and the San Antonio Spurs.

Spurs Sports and Entertainment is the premier provider of sports and entertainment in South Texas. They owns and operate the San Antonio Spurs, Austin Spurs (NBA G League), San Antonio FC (USL) and also manages the day-to-day operations of the AT&T Center and Toyota Field.

As part of the partnership, Canon Medical and the Spurs will collaborate on advancing medical imaging innovation to benefit everyone from high-performance athletes to weekend warriors and beyond.

“The Spurs are thrilled to partner with Canon Medical because they believe in using their technology to better humanity,” said RC Buford, CEO of Spurs Sports & Entertainment.  “We want to work with curious companies who have a learner mindset and are willing to bring new ideas forward. With a focus on today, we are always planning for tomorrow, and we believe this relationship will help us compete at the highest level.”

The collaboration between Canon Medical and SS&E began in 2016 after Buford and a group of Spurs executives visited Ciutat Esportiva Joan Gamper, the training complex for FC Barcelona.  In his visit, Buford learned how Canon Medical was at the forefront of diagnostic imaging. Since then, the Spurs identified Canon Medical as a critical part of their player care program and have been participating in Canon Medical’s professional education programs.

“At Canon Medical, our ‘Made For Life’ philosophy drives us to deliver innovative solutions to improve the quality of life for all people,” said Yuji Hamada, CEO of Canon Medical Systems USA, Inc. “The San Antonio Spurs embody that belief, which makes them an ideal partner. As the Spurs continue to perform as one of the highest-level teams in U.S. professional sports, it is our goal to work with the best clubs in the U.S. and globally so that we can take what we learn from elite athletes and apply it to all people.”

Additional information about the partnership will be highlighted through the Spurs social channels in the coming months.  Click here to watch a video on the partnership.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version